These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 1371718

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model.
    Gleave ME, Sato N, Sadar M, Yago V, Bruchovsky N, Sullivan L.
    J Cell Biochem; 1998 Jun 01; 69(3):271-81. PubMed ID: 9581866
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Hormone release and intermittent hormonal therapy in the LN CaP model of human prostate cancer].
    Gleave M, Santo N, Rennie PS, Goldenberg SL, Bruchovsky N, Sullivan LD.
    Prog Urol; 1996 Jun 01; 6(3):375-85. PubMed ID: 8763692
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel.
    Jackson JK, Gleave ME, Yago V, Beraldi E, Hunter WL, Burt HM.
    Cancer Res; 2000 Aug 01; 60(15):4146-51. PubMed ID: 10945622
    [Abstract] [Full Text] [Related]

  • 8. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB, Hayward SW, Kasper S, Matusik RJ.
    Cancer Res; 2004 Aug 01; 64(15):5489-95. PubMed ID: 15289359
    [Abstract] [Full Text] [Related]

  • 9. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
    Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y, Gao AC.
    Prostate; 2006 Jul 01; 66(10):1070-5. PubMed ID: 16637076
    [Abstract] [Full Text] [Related]

  • 10. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T, Lin FF, Rao P, Lin MF.
    Prostate; 2003 Jun 01; 55(4):247-58. PubMed ID: 12712404
    [Abstract] [Full Text] [Related]

  • 11. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model.
    Cheng L, Zhang S, Sweeney CJ, Kao C, Gardner TA, Eble JN.
    Anticancer Res; 2004 Jun 01; 24(4):2135-40. PubMed ID: 15330153
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
    Rekasi Z, Schally AV, Plonowski A, Czompoly T, Csernus B, Varga JL.
    Prostate; 2001 Aug 01; 48(3):188-99. PubMed ID: 11494334
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor.
    Eder IE, Hoffmann J, Rogatsch H, Schäfer G, Zopf D, Bartsch G, Klocker H.
    Cancer Gene Ther; 2002 Feb 01; 9(2):117-25. PubMed ID: 11857028
    [Abstract] [Full Text] [Related]

  • 15. Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model.
    Tuxhorn JA, McAlhany SJ, Dang TD, Ayala GE, Rowley DR.
    Cancer Res; 2002 Jun 01; 62(11):3298-307. PubMed ID: 12036948
    [Abstract] [Full Text] [Related]

  • 16. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.
    Gotoh A, Ko SC, Shirakawa T, Cheon J, Kao C, Miyamoto T, Gardner TA, Ho LJ, Cleutjens CB, Trapman J, Graham FL, Chung LW.
    J Urol; 1998 Jul 01; 160(1):220-9. PubMed ID: 9628654
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological inhibition of FGF receptor signaling inhibits LNCaP prostate tumor growth, promatrilysin, and PSA expression.
    Udayakumar TS, Bair EL, Nagle RB, Bowden GT.
    Mol Carcinog; 2003 Oct 01; 38(2):70-7. PubMed ID: 14502646
    [Abstract] [Full Text] [Related]

  • 18. Human prostate cancer progression models and therapeutic intervention.
    Chung LW, Kao C, Sikes RA, Zhau HE.
    Hinyokika Kiyo; 1997 Nov 01; 43(11):815-20. PubMed ID: 9436028
    [Abstract] [Full Text] [Related]

  • 19. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors.
    Kiyama S, Morrison K, Zellweger T, Akbari M, Cox M, Yu D, Miyake H, Gleave ME.
    Cancer Res; 2003 Jul 01; 63(13):3575-84. PubMed ID: 12839944
    [Abstract] [Full Text] [Related]

  • 20. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
    Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, Nelson C, Gleave M.
    Cancer Res; 2005 Dec 01; 65(23):11083-93. PubMed ID: 16322258
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.